SCHEMBL7397226

SCHEMBL7397226

NC1CCN(CCCOc2ccc(F)cc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.65
HRH1 P35367 2/20 0.65
HRH2 P25021 1/20 0.65
HTR1A P08908 3/20 0.64
DRD2 P14416 3/20 0.64
HTR2A P28223 3/20 0.64
DRD3 P35462 3/20 0.64
DRD1 P21728 2/20 0.64
DRD5 P21918 1/20 0.64
MEN1 O00255 1/20 0.61
LMNA P02545 1/20 0.61
HTT P42858 1/20 0.61
KMT2A Q03164 1/20 0.61
USP2 O75604 1/20 0.60
ALDH1A1 P00352 1/20 0.60
HPGD P15428 1/20 0.60
SIGMAR1 Q99720 2/20 0.58
TMEM97 Q5BJF2 1/20 0.58
LTA4H P09960 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8055586 0.98 HRH3 (0.64) HRH3HRH1HRH2HTR1ADRD2
SCHEMBL7818635 0.95 MEN1 (0.68) HRH3HRH1HRH2HTR1ADRD2
SCHEMBL9046298 0.94 LMNA (0.71) HRH3HRH1HRH2HTR1ADRD2
Hydrochloric Acid SCHEMBL8058655 0.94 LMNA (0.67) HRH3HRH1HRH2HTR1ADRD2
SCHEMBL5568576 0.94 LTA4H (0.65) HRH3HRH1HRH2HTR1ADRD2
SCHEMBL13698800 0.85 USP2 (0.73) HRH3HRH1HRH2HTR1ADRD2
SCHEMBL1728918 0.85 USP2 (0.78) HRH3HRH1HRH2HTR1ADRD2
SCHEMBL6296208 0.85 HTR1A (0.61) HRH3HRH1HTR1ADRD2HTR2A
SCHEMBL19705172 0.85 SIGMAR1 (0.74) HRH3HRH1HRH2HTR1ADRD2
SCHEMBL25540765 0.85 HRH3 (0.65) HRH3HRH1HRH2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0842174-B1 HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA PF MEDICAMENT (FR) 2001-10-04 EP disclosed
US-6117882-A 5-HT4 agonists and antagonists ELI LILLY AND COMPANY (US) 2000-09-12 US disclosed
US-6069152-A NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS ELI LILLY AND COMPANY (US) 2000-05-30 US disclosed
US-5959121-A Process for preparing 3-substituted indazoles ELI LILLY AND COMPANY (US) 1999-09-28 US disclosed
US-5914405-A Process for preparing 3-substituted indazoles ELI LILLY AND COMPANY (US) 1999-06-22 US disclosed
WO-1999017772-A1 5HT4 AGONISTS AND ANTAGONISTS ELI LILLY AND COMPANY (US) 1999-04-15 WO disclosed
WO-1999018080-A1 PROCESS FOR PREPARING 3-SUBSTITUTED INDAZOLES ELI LILLY AND COMPANY (US) 1999-04-15 WO disclosed
EP-0908459-A1 5-HT4 Agonists and antagonists ELI LILLY AND COMPANY (US) 1999-04-14 EP disclosed
EP-0908452-A2 Process for preparing 3-substituted indazoles ELI LILLY AND COMPANY (US) 1999-04-14 EP disclosed
EP-0842174-A1 HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA PIERRE FABRE MEDICAMENT (FR) 1998-05-20 EP disclosed
WO-1997005134-A1 HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA PIERRE FABRE MEDICAMENT (FR) 1997-02-13 WO disclosed
WO-1996012718-A1 NOUVELLES 2-[1-(φ-PHENOXYALCOYLPIPERIDIN-4-YL)AMINOMETHYLENE]-2H-BENZOFURAN-3-ONES SUBSTITUEES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE PIERRE FABRE MEDICAMENT (FR) 1996-05-02 WO disclosed
US-5202318-A Antiserotonine, antiemetic agents SYNTEX (U.S.A.) INC. (US) 1993-04-13 US disclosed
WO-1992021673-A1 NOVEL AZABICYCLOBENZISOQUINOLINES SYNTEX (U.S.A.) INC. (US) 1992-12-10 WO disclosed
US-5132311-A Prolonging cardiac action potential repolarization G. D. SEARLE & CO. (US) 1992-07-21 US disclosed